Bibliografía
1. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-82.
2. Hachimi-Idrissi S, Coffey F, Hautz WE, Leach R, Sauter TC, Sforzi I, et al. Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines-part 1: Assessment. Intern Emerg Med. 2020;15(7):1125-39.
3. Erazo MA, Pérez L, Colmenares CC, Álvarez H, Suárez I, Mendivelso F. Prevalencia y caracterización del dolor en pacientes hospitalizados. Revista de la Sociedad Española del Dolor. 2015;22(6):241-8.
4. Hoffmann F, Meinecke P, Freitag MH, Glaeske G, Schulze J, Schmiemann G. Who gets dipyrone (metamizole) in Germany? Prescribing by age, sex and region. J Clin Pharm Ther. 2015;40(3):285-8.
5. Ramacciotti AS, Soares BGO, Atallah AN. Dipyrone for acute primary headaches. Cochrane Database Syst Rev. 2007;2:CD004842.
6. Derry S, Faura C, Edwards J, McQuay HJ, Andrew Moore R. Single dose dipyrone for acute postoperative pain. Cochrane Database of Systematic Reviews. 2010;9:CD003227.
7. Gaertner J, Stamer UM, Remi C, Voltz R, Bausewein C, Sabatowski R, et al. Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat Med. 2017;31(1):26-34.
8. Nikolova I, Petkova V, Tencheva J, Benbasat N, Voinikov J, Danchev N. Metamizole: A review profile of a well-known “forgotten” drug. Part II: Clinical profile. Biotechnology & Biotechnological Equipment. 2013;27(2):3605-19.
9. ATC/DDD Index [Internet]. WHO; 2023 [consultado el 5 de julio de 2022]. Disponible en: https://www.whocc.no/atc_ddd_index/
10. Estadísticas de Medicamentos, MEDCOL-STAT [Internet]. Ministerio de Salud de Colombia; 2022 [consultado el 5 de abril de 2022]. Disponible en: https://pospopuli.minsalud.gov.co/MEDCOL-STAT /POSEstadisticasMedicamentos.aspx
11. Pinilla-Monsalve GD, Reyes-Rueda M, Pinilla-Monsalve LA. Problemas y reacciones adversas relacionadas con analgésicos opioides en Colombia. Rev Neurol. 2021;73:39.
12. Frome EL, Checkoway H. Use of Poisson regression models in estimating in estimating incidence rates and ratios. American Journal of Epidemiology. 1985;121(2):309-23.
13. González-Cárdenas VH, Laverde-Gaona LA, Cabarique-Serrano SH, Chávez-Rojas N, Reina-Sierra JA, Infante JS, et al. Analysis of the incidence of adverse events related to the administration of dipyrone. Colombian Journal of Anesthesiology. 2018;46(2):119-25.
14. Machado-Alba JE, Cardona-Trejos EA, Sánchez-Morales LV, Rodríguez-Ramírez LF. Identificación de reacciones adversas medicamentosas en pacientes tratados con dipirona en un hospital de tercer nivel. CES Medicina. 2019;33(1):13-20.
15. Hernández-Salazar A, Rosales SP de L, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37(7):899-902.
16. Trautmann A, Brockow K, Stoevesandt J. Metamizole-induced reactions as a paradigm of drug hypersensitivity: Non-allergic reactions, anaphylaxis, and delayed-type allergy. Clin Exp Allergy. 2020;50(9):1103-6.
17. Blanca-López N, Pérez-Sánchez N, Agúndez JA, García-Martin E, Torres MJ, Cornejo-García JA, et al. Allergic reactions to metamizole: Immediate and delayed responses. Int Arch Allergy Immunol. 2016;169(4):223-30.
18. Hoffmann F, Bantel C, Jobski K. Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985‐2017. Basic & Clinical Pharmacology & Toxicology. 2020;126(2):116-25.
19. Blaser LS, Tramonti A, Egger P, Haschke M, Krähenbühl S, Rätz Bravo AE. Hematological safety of metamizole: Retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol. 2015;71(2):209-17.
20. Stammschulte T, Ludwig WD, Mühlbauer B, Bronder E, Gundert-Remy U. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012. European Journal of Clinical Pharmacology. 2015;71(9):1129-38.
21. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002;58(4):265-74.
22. Shah RR. Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity? J Clin Pharm Ther. 2019;44(1):129-33.
23. Vlahov V, Bacracheva N, Tontcheva D, Naumova E, Mavrudieva M, Ilieva P, et al. Genetic factors and risk of agranulocytosis from metamizol. Pharmacogenetics. 1996;6(1):67-72.
24. Lutz M. Metamizole (dipyrone) and the liver: A review of the literature. J Clin Pharmacol. 2019; 59(11):1433-42.
25. Collares EF, Troncon LEA. Effects of dipyrone on the digestive tract. Braz J Med Biol Res. 2019;52(2):e8103.
26. Weber S, Benesic A, Neumann J, Gerbes AL. Liver injury associated with metamizole exposure: Features of an underestimated adverse event. Drug Saf. 2021;44(6):669-80.
Artículos relacionados
Ibuprofeno intravenoso y combinaciones farmacológicas
Abad Gurumeta A, Bergese SD, Zuleta-Alarcón A, Fiorda- Díaz J, Martínez Ruiz A, Casans Francés R, Ripollés Melchor J y Calvo Vecino JM. Ibuprofeno intravenoso y combinaciones farmacológicas. Rev Soc Esp Dolor 2016;23(Supl. I):31-34.